Sai Life Sciences
Market cap ₹37,992 Cr
- P/E
- 101.71
- Day range
- ₹1,750.40 – ₹1,819.20
- 52-week range
- ₹783.85 – ₹1,954.80
- Volume
- 11.87 L
- Open
- ₹1,751.50
- Prev close
- ₹1,751.50
Latest results · Q2 FY27(consolidated)Revenue ₹659 Cr+22.5%Profit ₹98 Cr+17.3%Margin 14.9%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
SAILIFE in NSE indices and F&O
Research profile
Composite 62 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.0%
- Graham no.
- ₹226.04
- vs Graham
- -87.4%
- ROE ÷ P/B
- 1.1%
- 12-1 mom.
- +53.2%
- Return / vol
- 2.72
- Magic Formula
- #474
- FCF yield
- -0.2%
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Sai Life SciencesSAILIFE | ₹37,992 Cr | 101.71 | 14.17 | 15.1% | 20.0% | 28.0% | 0.23 | +22.7% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 49m agoHeadlines about Sai Life Sciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 100.0
- Price / Book
- 14.08
- ROE (FY26)
- 15.1%
- ROCE (latest year)
- 20%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹1,630.61
- Price above
- 50-day
- ₹1,577.71
- Price above
- 200-day
- ₹1,248.37
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 | 659 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 | 472 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 | 186 |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% | 28% |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 | 11 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 | 48 |
| Profit before tax | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 | 131 |
| Tax % | 25% | 26% | -25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 | 98 |
| EPS in Rs | — | — | — | — | ₹2.59 | ₹4.24 | ₹2.90 | ₹4.00 | ₹4.75 | ₹4.92 | ₹3.45 | ₹4.63 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-37 days since Mar 2021
-30 days since Mar 2021
-48 days since Mar 2021
-20 days since Mar 2021
+8 days since Mar 2021
Strengths, risks & growth
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries [1]
Strengths
- Company has delivered good profit growth of 42.2% CAGR over last 5 years
Risks
- Stock is trading at 14.2 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
- Working capital days have increased from 49.2 days to 69.8 days
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +24%
- 3 Years
- +22%
- TTM
- +16%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +42%
- 3 Years
- +227%
- TTM
- +33%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +105%
Return on Equity
- 10 Years
- —
- 5 Years
- +9%
- 3 Years
- +13%
- Last Year
- +15%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 34.70% | 34.61% | 34.53% | 34.50% | -0.03 pp |
| FII | 21.41% | 21.17% | 19.65% | 19.91% | +0.26 pp |
| DII | 31.41% | 31.54% | 32.71% | 32.32% | -0.39 pp |
| Public | 12.49% | 12.69% | 13.11% | 13.25% | +0.14 pp |
Filed with NSE for Sept 2026: promoters 34.50%, public 65.50%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 29.56% (+0.09 pp)- Promoters34.5%
- Foreign institutions19.9%
- Mutual funds29.6%
- Insurance2.6%
- Other domestic institutions0.1%
- Retail5.0%
- Others8.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Nippon India Small Cap Fund | 2.75% | 1.33% | +0.24 pp |
| Invesco India Large & Mid Cap Fund | 1.79% | 5.36% | +0.57 pp |
| Nippon India Multi Cap Fund | 1.75% | 1.21% | +0.37 pp |
| Invesco India Midcap Fund | 1.58% | 3.71% | +0.65 pp |
| Axis Small Cap Fund | 1.55% | 1.97% | +0.32 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 35.6%
- Downside volatility
- 31.9%
- Worst 5% of days
- 3.4%
- Average of that tail
- 4.6%
- Max drawdown (1Y)
- 18.6%
- Below its peak
- 7.3%
Against the market
- Beta vs Nifty 50
- 0.80
- Correlation
- 0.31
- Relative strength (3M)
- +22.4%
- ATR (14)
- 4.6%
Return
- Return 1M
- +28.7%
- Return 3M
- +26.2%
- Return 6M
- +60.7%
- Return 1Y
- +97.1%
- vs 200-day average
- +43.2%
Momentum
- RSI (14)
- 62.2
- MACD histogram
- 18.72
- Stochastic %K
- 65.4
- ADX (14)
- 35.1
- +DI / −DI
- 28.6 / 15.7
- Money flow index
- 86.4
Participation
- Delivery (20d avg)
- 42.8%
- vs its 60-day baseline
- -6.6 pts
- Volume vs 20-day
- -0.2σ
- Close vs day's VWAP
- -0.7%
- 52-week position
- 88 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Free cash flow
- -₹84 Cr
- FCF yield
- -0.2%
- Cash conversion
- 1.46
- Accruals ratio
- -0.044
- Net debt
- ₹589 Cr
- Net debt / equity
- 0.22
- EV / sales
- 16.27
- Capex intensity
- 27.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
Company announcements
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026.
Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited financial results ....
Closure of Trading Window relating to Unaudited Financial Result for the Second Quarter and Half Year Ending on 30th September 2026
Allotment of 24,000 Equity Shares having Face Value of Rs. 1/- as per Company's ESOP Plan
Voting Results and Scrutinizer's Report of 27th Annual General Meeting (AGM) of the Company
Proceedings of 27th Annual General Meeting (AGM) of the Company
Investors Conference - 18th September 2026
Investors Conference - 14th September 2026
Allotment of 80,600 Equity shares having Face Value ?1/- each as per Company's ESOP Plans
Newspaper Publication relating to 27th AGM (Post-dispatch Advt.)
Please refer the attachment
Business Responsibility and Sustainability Report (BRSR) and ESG Databook of Sai Life Sciences Limited for the FY 2025-26
Integrated Annual Report of Sai Life Sciences Limited for the FY 2025-26
Notice of 27th Annual General Meeting (AGM) of the Company
Newspaper Publication relating to 27th AGM (Pre-dispatch Advt.)
Filed with BSE (scrip 544306); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlides
Credit ratings
- Rating update · 13 Nov from fitch
- Rating update · 26 Feb from icra
- Rating update · 14 Aug 2025 from fitch
- Rating update · 15 May 2024 from fitch
- Rating update · 28 Feb 2023 from fitch
- Rating update · 8 Dec 2021 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Sai Life Sciences: common questions
Answered from the figures on this page.